Online citations, reference lists, and bibliographies.

Chiral Inversion Of The Second Generation IMiD CC-4047 (ACTIMID ) In Human Plasma And Phosphate-buffered Saline.

Steve K. Teo, Yong Chen, George W. Muller, Roger Shen-Shu Chen, Steve D. Thomas, David I. Stirling, Reddy S Chandula
Published 2003 · Medicine, Chemistry
Cite This
Download PDF
Analyze on Scholarcy
Share
CC-4047 is a racemic second-generation immunomodulatory drug currently in clinical development for various oncologic indications. It has potent effects on key cytokines including tumor necrosis factor-alpha, interleukin (IL-10), and interferon (IFN-gamma). The S-isomer of CC-4047 has been reported to be the more potent enantiomer of the racemate. In this article we report on the rapid racemization of the S-isomer of CC-4047 in human plasma and phosphate-buffered saline. These results support the further development of the racemate instead of the S-isomer.



This paper is referenced by
10.1002/jssc.201600354
Liquid chromatography with mass spectrometry enantioseparation of pomalidomide on cyclodextrin-bonded chiral stationary phases and the elucidation of the chiral recognition mechanisms by NMR spectroscopy and molecular modeling.
Zoltán-István Szabó (2016)
10.1002/9781118075647.CH10
Toxicology of Chiral Drugs
Guang Yang (2011)
10.2147/CPAA.S171735
A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension
Yan Li (2018)
10.1002/cpdd.470
An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
Yan Li (2019)
10.1002/chir.22563
Chiral Separation of Uncharged Pomalidomide Enantiomers Using Carboxymethyl-β-Cyclodextrin: A Validated Capillary Electrophoretic Method.
Zoltán-István Szabó (2016)
10.1016/j.bmc.2015.02.056
Synthetic approaches to the 2013 new drugs.
Hong Xia Ding (2015)
10.1093/toxsci/kfp097
Chiral toxicology: it's the same thing...only different.
Silas Smith (2009)
10.22159/ijap.2017v9i1.15653
A UPLC-MS/MS METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF POMALIDOMIDE FROM HUMAN PLASMA
D. Atul Vasanth (2016)
10.1002/jcph.1145
In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
Yan Li (2018)
10.1016/B978-0-444-62649-3.00011-9
Chapter 11 - Other Nonbiological Approaches to Targeted Cancer Chemotherapy
Carmen Avendaño (2015)
Thalidomide and its analogs: a potential immunomodulatory alternative for treating liver diseases and cirrhosis
Fernández Martínez (2011)
10.1038/s41598-018-19202-7
Structural basis of thalidomide enantiomer binding to cereblon
Tomoyuki Mori (2018)
10.1517/13543776.14.2.215
Thalidomide analogues: derivatives of an orphan drug with diverse biological activity
Frederick A Luzzio (2004)
10.1002/jcph.455
Population Pharmacokinetics of Pomalidomide
Yan Li (2015)
10.1002/hon.2485
Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma.
Camille Morival (2017)
Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide Rand S-Enantiomers
Yan Li (2014)
10.1093/toxsci/kfr086
Fluorothalidomide: a characterization of maternal and developmental toxicity in rabbits and mice.
Crystal J J Lee (2011)
10.2147/CPAA.S167017
Distribution of pomalidomide into semen of healthy male subjects after multiple doses
Yan Li (2018)
10.1073/pnas.1417832112
Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs
Vincent Jacques (2015)
Molecular Mechanisms and Determinants of Species Sensitivity in Thalidomide Teratogenesis
Crystal J J Lee (2013)
10.1002/chir.22236
Bidirectional chiral inversion of trantinterol enantiomers after separate doses to rats.
Feng Qin (2013)
10.1016/j.jpba.2013.08.036
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.
Yao Jiang (2014)
10.1124/jpet.114.215251
Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide R- and S-Enantiomers
Yan Li (2014)
10.2147/CPAA.S144606
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
Yan Li (2017)
Semantic Scholar Logo Some data provided by SemanticScholar